Compare WEYS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | DSGN |
|---|---|---|
| Founded | 1906 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.3M | 853.8M |
| IPO Year | 1995 | 2021 |
| Metric | WEYS | DSGN |
|---|---|---|
| Price | $47.74 | $12.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 19.8K | ★ 655.8K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $276,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.25 | $5.28 |
| 52 Week High | $48.68 | $17.25 |
| Indicator | WEYS | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 35.99 |
| Support Level | $43.59 | $11.82 |
| Resistance Level | $48.68 | $13.54 |
| Average True Range (ATR) | 1.30 | 0.76 |
| MACD | 0.21 | -0.22 |
| Stochastic Oscillator | 73.45 | 10.33 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, South Africa, and Australia.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.